2,641 Cases Currently Pending in the Actos Multidistrict Litigation:...
According to the Judicial Panel on Multidistrict Litigation, on November 18, there were 2,641 cases pending in the Actos Multidistrict Litigation. In light of this news, AttorneyOne, a recognized...(PRWeb December 10, 2013)Read the full story at http://www.prweb.com/releases/2013/11/prweb11349563.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 10, 2013 Category: Pharmaceuticals Source Type: news
Actos Lawsuit News: Nation’s Third Actos Trial Involving Bladder...
The Firm is investigating Actos lawsuits on behalf of individuals who allegedly developed bladder cancer due to long-term use of Actos.(PRWeb December 09, 2013)Read the full story at http://www.prweb.com/releases/actos-lawsuit/actos-bladder-cancer/prweb11405689.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 10, 2013 Category: Pharmaceuticals Source Type: news
Prevention of Diabetes With Pioglitazone in ACT NOWPrevention of Diabetes With Pioglitazone in ACT NOW
Does prophylactic use of this glitazone prevent diabetes? Diabetes (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Kentucky Defective Drug Attorneys Represent Victims in Actos Mass Tort
Louisville’s Gray & White law firm is representing individuals who may have suffered serious side effects from the type 2 diabetes drug Actos(PRWeb November 13, 2013)Read the full story at http://www.prweb.com/releases/2013/11/prweb11324279.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 14, 2013 Category: Pharmaceuticals Source Type: news
Actos Accused in Trial for Cancer Death: Now, AttorneyOne Can Provide...
Businessweek published on September 25 that Takeda allegedly deceived patients and doctors about the risks of Actos, according to the second case that went to trial. In light of this news,...(PRWeb October 25, 2013)Read the full story at http://www.prweb.com/releases/2013/10/prweb11267881.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 27, 2013 Category: Pharmaceuticals Source Type: news
Pioglitazone Increases Risk for Macular EdemaPioglitazone Increases Risk for Macular Edema
For those who received the thiazolidinedione, the risk of macular edema was 5 times greater than those who did not receive pioglitazone. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 1, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Concerns over diabetes treatment
Patients prescribed sulfonylureas have far higher all-cause mortality than those on metformin, study suggestsRelated items from OnMedicaMost-used diabetes drug works differently than previously thoughtMetformin may delay ageing processCertain statins can raise risk of developing diabetesCaution urged over intensive glucose controlExperts query risks of pioglitazone (Source: OnMedica Latest News)
Source: OnMedica Latest News - September 26, 2013 Category: UK Health Source Type: news
EU marketing authorization granted for three new type 2 diabetes therapies, Vipidia, Vipdomet and Incresync
Takeda Pharmaceutical Company Limited (Takeda) today announced that the European Commission has granted Marketing Authorization (MA) for Vipidia[TM] (alogliptin), a dipeptidyl peptidase IV (DPP-4) inhibitor, for the treatment of type 2 diabetes patients who are uncontrolled on existing therapies[1]-[3]and for the fixed-dose combination (FDC) therapies Vipdomet[TM] (alogliptin with metformin) and Incresync[TM] (alogliptin with pioglitazone)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 25, 2013 Category: Consumer Health News Tags: Diabetes Source Type: news
Diabetes Drug Alogliptin Plus Combos Approved in EuropeDiabetes Drug Alogliptin Plus Combos Approved in Europe
The European Commission grants marketing authorization to the DPP-4 inhibitor alogliptin alone and in fixed-dose combination with either metformin or pioglitazone. International Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 24, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
Actos Lawsuit News: Bernstein Liebhard LLP Notes Scheduling of Next...
The Firm is investigating Actos bladder cancer lawsuits on behalf of patients who developed the disease, allegedly due to extended use of Actos.(PRWeb September 14, 2013)Read the full story at http://www.prweb.com/releases/actos-lawsuit/actos-bladder-cancer/prweb11123365.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 17, 2013 Category: Pharmaceuticals Source Type: news
Lawsuit Alleges Takeda Pharmaceutical Co., Maker of Diabetes Drug...
Plaintiff’s counsel alleges that Takeda Pharmaceutical Co. knew about the dangers of its diabetes drug Actos “by 2005 at the latest,” but failed to issue a warning until six years afterward, Bloomberg...(PRWeb September 06, 2013)Read the full story at http://www.prweb.com/releases/Actos_trial_Bloomberg/09/prweb11098139.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 8, 2013 Category: Pharmaceuticals Source Type: news
New Actos Bladder Cancer Lawsuit: Now, AttorneyOne Can Provide Advice
Court data indicate that, on August 19, a West Virginia man filed a lawsuit in Louisiana Western District Court (case no. 6:2013cv02512) alleging that he suffered bladder cancer caused by Actos. In...(PRWeb September 02, 2013)Read the full story at http://www.prweb.com/releases/2013/9/prweb11080472.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 3, 2013 Category: Pharmaceuticals Source Type: news
Actos Lawsuits Move Forward Following Latest Status Conference in...
The Firm is currently offering confidential Actos lawsuit evaluations to long-term users of Actos who have been diagnosed with bladder cancer.(PRWeb August 31, 2013)Read the full story at http://www.prweb.com/releases/actos-lawsuit/actos-bladder-cancer/prweb11079665.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 3, 2013 Category: Pharmaceuticals Source Type: news
Takeda and Zinfandel begin Phase III trial of low dose pioglitazone
Takeda Pharmaceutical Company and partner, Zinfandel Pharmaceuticals, have begun Phase III trial, also known as TOMMORROW, to assess investigational low dose pioglitazone. (Source: Drug Development Technology)
Source: Drug Development Technology - August 26, 2013 Category: Pharmaceuticals Source Type: news
Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming...
The Firm is currently offering confidential Actos lawsuit evaluations to patients who may have developed bladder cancer, allegedly due to long-term use of the diabetes drug.(PRWeb August 18, 2013)Read the full story at http://www.prweb.com/releases/actos-lawsuit/actos-bladder-cancer/prweb11036674.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 20, 2013 Category: Pharmaceuticals Source Type: news
